New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
20:25 EDTKO, KO, SCHW, SCHW, NTRS, NTRS, CMA, CMA, WABC, WABC, CNSI, CNSI, PBY, PBY, JNJ, JNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
News For JNJ;KO;SCHW;NTRS;CMA;WABC;CNSI;PBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 20, 2014
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
09:13 EDTCMAComerica downgraded to Hold from Buy at Rafferty Capital
Rafferty downgraded Comerica to Hold based on concerns the company will not be able to maintain its net interest income combined with operating expenses over the next few quarters. Price target lowered to$48 from $59. Note that Bernstein, Nomura, and Sandler O'Neill upgraded shares this morning.
08:16 EDTCMAComerica upgraded to Buy from Hold at Sandler O'Neill
Sandler O'Neill upgraded Comerica to Buy with a $49 price target due to valuation and increased confidence in cost controls. Note this is the third upgrade of the day.
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
08:07 EDTKOCoca-Cola Bottling to exchange franchise territory with Coca-Cola
Subscribe for More Information
06:49 EDTCMAComerica upgraded to Neutral from Reduce at Nomura
Nomura upgraded Comerica to Neutral based on reasonable valuation. Price target lowered to $41 from $42. Note that Bernstein upgraded shares to Market Perform this morning.
05:55 EDTCMAComerica upgraded to Market Perform from Underperform at Bernstein
Subscribe for More Information
October 17, 2014
16:55 EDTJNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
09:31 EDTNTRSNorthern Trust establishes South Korea office
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
06:47 EDTCMAComerica now sees FY14 average loans growth of about 5%
Subscribe for More Information
06:47 EDTCMAComerica sees slight growth in average loans in Q4
Subscribe for More Information
06:42 EDTCMAComerica reports Q3 EPS 82c, consensus 80c
Subscribe for More Information
October 16, 2014
15:26 EDTCMANotable companies reporting before tomorrow's open
Subscribe for More Information
14:47 EDTJNJRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
10:07 EDTKOCoca-Cola volatility elevated into Q3 and outlook
Subscribe for More Information
05:39 EDTNTRSNorthern Trust appointed by Westminster City Council for GBP1.9B mandate
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use